efprezimod alfa
Clinical trial activity
7 trials · 11 clinical orgs · 0 marketing orgs
Earliest trial started Feb 1, 2014 (NCT02650895)
Timeline
Indications
Studied for
- COVID-19 · Phase 3
- Dyslipidemias · Phase 2
- Graft vs Host Disease · Phase 3
- Healthy Volunteers · Phase 1
- Hematopoietic Stem Cell Transplantation · Phase 3
- HIV Infections · Phase 2
- Leukemia · Phase 2
- Leukemia, Myeloid, Acute · Phase 3
- Melanoma · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 3
- Neoplasms · Phase 1/Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 3
Mechanism of action
- High mobility group protein B1INHIBITOR
High mobility group protein B1 inhibitor
Components of injured cells (Danger-Associated Molecular Patterns, or DAMPs) activate the immune system. CD24 is a biological immunomodulator that can interact with DAMPs inhibiting their stimulation of the immune response. CD24Fc augments endogenous CD24 to potentially suppress severe immune response.
Box B
- Heat shock protein HSP90INHIBITOR
Heat shock protein HSP90 inhibitor
Components of injured cells (Danger-Associated Molecular Patterns, or DAMPs) activate the immune system. CD24 is a biological immunomodulator that can interact with DAMPs inhibiting their stimulation of the immune response. CD24Fc augments endogenous CD24 to potentially suppress severe immune response.
- Heat shock 70 kDa protein 1A/1BINHIBITOR
Heat shock 70 kDa protein 1A/1B inhibitor
Components of injured cells (Danger-Associated Molecular Patterns, or DAMPs) activate the immune system. CD24 is a biological immunomodulator that can interact with DAMPs inhibiting their stimulation of the immune response. CD24Fc augments endogenous CD24 to potentially suppress severe immune response.
Sialic acid-binding Ig-like lectin 10 modulator
Siglec receptors negatively regulate the immune system. CD24 interacts with Siglec 10 to selectively regulate host responses to stimulation by Danger-Associated Molecular Patterns. Recombinant CD24Fc augments endogenous CD24 to suppress a severe immune response.
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSFN12T66RMN ↗
- ChEMBLCHEMBL4297717 ↗
Also known as
- cd24fc
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04552704 | Phase 1/Phase 2 (Phase 2) | Oct 30, 2020 | National Cancer Institute (NCI), OncoImmune, Inc., University of California, Davis |
| NCT04060407 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2020 | OncoImmune, Inc., University of Utah |
| NCT04317040 | Phase 3 | Apr 8, 2020 | OncoImmune, Inc., University of Maryland |
| NCT04095858 | Phase 3 | Feb 15, 2020 | Indiana University, Ohio State University, OncoImmune, Inc., University of Michigan, Wayne State University |
| NCT03960541 | Phase 2 | Oct 31, 2019 | OncoImmune, Inc., University of Maryland |
| NCT02663622 | Phase 2 | Aug 1, 2016 | Ohio State University, OncoImmune, Inc., University of Michigan |
| NCT02650895 | Phase 1 | Feb 1, 2014 | Medpace, Inc., National Institute of Neurological Disorders and Stroke (NINDS), OncoImmune, Inc. |
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| OncoImmune, Inc. | For profit | 7 | 6 | 3 | 2014 |
| Ohio State University | Academic/Hospital | 2 | 0 | 2 | 2016 |
| University of Maryland | Academic/Hospital | 2 | 0 | 2 | 2019 |
| University of Michigan | Academic/Hospital | 2 | 0 | 2 | 2016 |
| Indiana University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Medpace, Inc. | For profit | 1 | 0 | 1 | 2014 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2020 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 0 | 1 | 2014 |
| University of California, Davis | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Utah | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Wayne State University | Academic/Hospital | 1 | 0 | 1 | 2020 |